PulseAGGREGATOR

Gathering headlines…

Pulse Aggregator

Crawls 10,000+ sources around the clock and organizes the noise into verified stories — de-duplicated, bias-scored, and auto-tagged, with blindspot detection, trend analytics, anomaly alerts, translation, and custom digests or RSS. All in one live dashboard.

Legal

Multiple Sacituzumab Tirumotecan (sac-TMT) Studies Selected as LBAs at ESMO 2026, OptiTROP-Lung04 and OptiTROP-Lung06 to be Presented in the Lung Cancer Session | Pulse Aggregator

← Back to feed

PR Newswire Asia

pressCenter

7h ago

Multiple Sacituzumab Tirumotecan (sac-TMT) Studies Selected as LBAs at ESMO 2026, OptiTROP-Lung04 and OptiTROP-Lung06 to be Presented in the Lung Cancer Sessiontranslating…

The 2026 European Society for Medical Oncology (ESMO) Congress will be held in Madrid, Spain, from October 23 to 27. Multiple Phase III clinical...

Factuality

73/100

Political Bias

Center

Ownership

PR Press Ltd

Country

Unknown

Region

Asia

Keywords#ESMO#Multiple#Cancer#Cancer Session#LBAs

Read Original ↗